NCT05499936

68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)

Peking Union Medical College Hospital

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma（ACC）

Detailed description

68Ga-FAPI is a positron labeled inhibitor of fibroblast activating protein, which has been widely used in malignant tumor imaging in recent years. Adenoid cystic carcinoma (ACC) is a rare epithelial malignant tumor, which usually originates from salivary glands. Its typical characteristics are long clinical course and high rate of distant metastasis. The purpose of this study was to investigate the clinical value of 68Ga Fapi pet/ct in metastatic adenoid cystic carcinoma.

Conditions

• 68Ga-FAPI PET/CT
• Metastatic Adenoid Cystic Carcinoma

Interventions

Type	Name	Description
DRUG	68Ga-FAPI	68Ga-FAPI were injected into the patients before the PET/CT scans

Timeline

• Start date: 2021-10-01
• Primary completion: 2022-10-01
• Completion: 2022-12-31
• First posted: 2022-08-12
• Last updated: 2022-08-12

Locations

1 site across 1 country: China